Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% ...
Adults with diabetes using an automated insulin delivery system had minimal change in time in range after switching ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...
This morning Belgian startup Indigo Diabetes announced a €38 million ($44.6 million) Series B funding round. This round included contributions from new investors Fund+, Ackermans&van Haaren, Capricorn ...
Diabetes remains one of the nation’s most prevalent and dangerous chronic conditions, affecting nearly 15% of U.S. adults and causing more than 100,000 deaths each year. As a response, the landscape ...
Continuous glucose monitoring (CGM)-derived metrics reliably identified cystic fibrosis-related diabetes in patients with cystic fibrosis. Additionally, a novel way of analysing CGM data called ...
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...
Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results